Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Mitsuhisa KomatsuHirotaka WatadaShizuka KanekoBue F Ross AgnerTomoyuki NishidaKohei KakuPublished in: Journal of diabetes investigation (2021)
IDegLira reduced HbA1c in Japanese participants with type 2 diabetes across baseline HbA1c , body mass index and age categories, without unexpected safety issues.